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SUMMARY 
Objectives: The knowledge about outcomes of infant vaccination against HBV infections using the DPT-HepB-Hib 
vaccine in Ghana is limited. This study therefore investigated the levels of immunity to HBV among children who 
received the DPT-HepB-Hib vaccine and HBsAg carriage in non-responders. Correlates for non-response or poor 
response were also investigated. 
Methods: Cross-sectional study. A major paediatric hospital in Accra. Four hundred and twenty four children be-
tween the ages of 5 to 32 months who had completed the full vaccination schedule for the DPT-HepB-Hib vaccine. 
Results: Of the 424 children, 358 (84.4%) developed anti-HBs while 340 (80.2%) developed ≥10 mIU/ml anti-HBs 
(sero-protection) and 3 had HBsAg. A binary logistic regression analysis showed that younger children were associ-
ated with sero-conversion (p=.022) and sero-protection (p=.021). For anti-HBs titres ≥100 mIU/ml age was a weaker 
but significant contributor (p=.041), as compared to the number of vaccines from different manufacturers the child 
used (p=.028). The mean age of those who used a single type of vaccine was higher (14.75 ± 6.056 months; n=268) 
than those who used vaccines from two or more manufacturers (11.96 ± 4.645 months; n=156), p= <.001 (CI: -3.897 
– 1.688), an indication that efforts to procure vaccine from same source when it was initially introduced are waning. 
Conclusions: There is still a residual possibility of infection with HBV in spite of infant vaccination. In the light of 
possible loss of anamnestic response over time, there is the need to consider a birth dose for HBV vaccination for all 
neonates or booster dose for infants who may not have received the vaccine at birth. Using vaccines from a single 
manufacturer is recommended. 
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INTRODUCTION 
There is evidence that mass infant vaccinations can re-
duce hepatitis B virus (HBV) infections in highly en-
demic environments resulting in drastic reduction of 
HBV transmission.1-4 Some of these programmes may 
not be limited to infants but may be extended to other 
age groups.2 The complete elimination of hepatitis B 
surface antigen (HBsAg) carriage in infants under 5 
years in South Africa 4, could therefore be a model for 
countries who are over a decade into HBV vaccination 
through the Expanded Programme of Immunization 
(EPI). 
 
Infant vaccination may not always achieve the desired 
short and long term results as hepatitis B antibody (anti-
HBs) levels may wane over time5, immunity to HBV 
antigens may not be sufficient in significant proportions 
of children6, a delayed second dose in an infant vaccina-
tion schedule in a national EPI programme may lead to 
the increased risk of infection7, and a loss to immune 
memory may occur resulting in the absence of an anam-
nestic response after encounter with HBV antigens.8 
There is therefore the need for a clearer understanding 
of the dynamics of immune responses in infants after 
they have received all three doses of hepatitis B vaccine 
during the first fourteen weeks of life. 
 
Even though data on the evaluation of the effectiveness 
of infant vaccination in the West African sub-region is 
still emerging5,6,9-12, the factors that may determine re-
sponses to vaccination in resource-limited settings are 
still unclear. Such gaps may lead to reduced adherence 
to protocols that provide maximum efficiency and will 
in such instances reduce the frequency of sero-
protection.13  
A systematic approach to the evaluation of ongoing 
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maximum benefits are derived. This is emphasized by 
the findings that infants in Cameroon did not respond 
well to the same HBV vaccination regimen as compared 
to those in the Gambia 6, and also that genetic factors 
may account for non-response.14 In countries where 
vaccines were administered at birth and subsequently 
using the EPI protocol, there has been residual infec-
tions in young adults in spite of the reduction in preva-
lence of HBV infections. 15,16 
 
It also seems that in the Gambia including a birth dose 
may help to give long lasting protection in adoles-
cence.17 Apart from providing early protection against 
the establishment of HBV infection in infants, the use of 
a birth dose has been associated with increased rates of 
individuals who actually complete the vaccination 
schedule.18,19 Furthermore, an early booster dose be-
tween 4-5 years may increase the number of children 
with sero-protection. 16 
 
Since the introduction of HBV vaccination in the EPI 
programme in 2002 in Ghana, few studies to evaluate 
the development of sero-protection against HBV infec-
tions in infants have been done11,20, and the manufactur-
ers of the supply of vaccines have been changed a num-
ber of times. Furthermore, limited information on HBV 
infections in children in Ghana suggests a very high 
prevalence in some parts of the country21, with no effec-
tive vaccination programmes at birth. In the absence of 
an institutionalized birth dose, there is the need to moni-
tor current vaccination programs for sero-protection 
rates and HBsAg carriage to estimate residual infections 
in our hyper endemic environment where prevalence 
rates are around 10% in different populations.22-25 
 
This study therefore reports the levels of immunity to 
HBV among children who received the DPT-HepB-Hib 
vaccine and HBsAg carriage in those who did not sero-
convert to anti-HBs (non-responders). Since immune 
recognition can wane 8, the factors that determine high 
(100 mIU/ml) anti-HBs titres were also determined. 
Correlates for non-response are also discussed. 
 
METHODS 
Study site and population 
The study was conducted at the Princess Marie Louis 
Children’s Hospital (PML) located in the central busi-
ness district of Accra, the capital city of Ghana. This 
hospital is a major paediatric hospital, which caters for 
children from different parts of the capital city. A cross-
section of 424 children between the ages of 5-32 months 
who had completed their DPT-HepB-Hib vaccination 
schedules for at least one month was selected using a 
convenient sampling approach. These children were 
visiting the facility for varying health conditions from 
March 2012 to January 2013. The study was approved 
by the Ethical and Review Committee of the School of 
Medicine and Dentistry, University of Ghana, and writ-
ten informed consent was sought from all parents on 
behalf of their children after the nature and consequenc-
es of the study was fully explained. 
 
A structured questionnaire was used to obtain demo-
graphic data and information for the following varia-
bles; timeliness (T6, 10, 14), whether the study participant 
received the vaccine at scheduled times on the 6th, 10th 
and 14th weeks after birth; type of vaccines (V1/>1), 
whether the vaccines received by the child were from 
one manufacturer or two or more manufacturers (GSK, 
Belgium; Berna Biotech, Korea; Panacea Biotech, In-
dia); and exclusive breast feeding (EBF). Attempts were 
made to retrieve antenatal records for the mothers to 
determine their HBsAg status prior to parturition but 
this was unsuccessful. 
 
Blood collection and laboratory testing 
After informed written consent had been sought from 
parents or guardians, blood from the children which had 
already been collected with EDTA anticoagulant tubes 
for other diagnostic purposes were retrieved from the 
PML laboratory and plasma obtained by centrifuging at 
4500 RPM for 3 minutes using the EBA 20 table-top 
centrifuge (Hettich Zentrifugen, Tuttlingen, Germany). 
Plasma was kept at -20°C for short-term storage until 
serological testing was done. Plasma was analysed qual-
itatively and quantitatively for anti-HBs using a sand-
wich EIA principle (Antisurase B-96 ELISA, General 
Biologicals, Corp., Taiwan).  
 
A 1000 mIU/ml standard was diluted with normal hu-
man plasma which had tested negative for anti-HBs, 
anti-HBc IgM, anti-HBc IgG, and HBsAg, to make 1/2, 
1/4, 1/8, 1/16, 1/32, 1/64 dilutions and included in ELI-
SA runs to facilitate quantitative analysis. The cut-off 
value for each ELISA plate was used to determine the 
children who had any level of anti-HBs, and these were 
further categorized into those with ≥10 mIU/m and 
≥100 mIU/ml of anti-HBs using appropriate standards.  
 
All standards were from General Biologicals, Corp., 
Taiwan, and anti-HBs determination was done in dupli-
cates. In order to identify those with HBsAg carriage, 
all children who had not developed anti-HBs were 
screened for HBsAg with the Surase B-96 ELISA (Gen-
eral Biologicals Corp., Taiwan) and supplemental test-
ing done with the Wondfo rapid test (Guangzhou Wonfo 
Biotech Inc., China).  
Qualitative screening for anti-HBc IgG was done for the 
354 children with detectable anti-HBs with an ELISA 
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have presumptive idea of the children who may have 
had natural infections with HBV. Supplemental testing 
for anti-HBc IgG was done with Anticorase B-96 ELI-
SA (General Biologicals, Corp., Taiwan) for 21 of the 
45 plasma samples that were reactive for anti-HBc IgG 
with the Foresight ELISA. 
 
Data analysis 
The primary study outcomes determined were children 
who had anti-HBs of ≥10 mIU/ml (sero-protection) 26, 
and those who had HBsAg. The independent t-test and 
chi squared test were used to determine the correlates 
for seroconversion, sero-protection and having high 
anti-HBs.  
 
A stepwise bivariate logistic regression was also done to 
determine the most important determinants for serocon-
version, sero-protection and having high anti-HBs (≥ 
100 mIU/ml). A spearman rank correlation was done to 
determine the correlation between actual anti-HBs titres 
and age. The SPSS V17 software (SPSS for Windows, 
SPSS Inc., Chicago) was used for all statistical analysis 
and p values of <0.05 considered statistically significant 
for all analysis. 
 
RESULTS 
Description of population 
Of the total number of participants tested, 215 (50.7%) 
and 209 (49.3%) were males and females respectively. 
The mean and median age of the study participants were 
13.7 and 13.0 months respectively. The highest frequen-
cy was seen among children who were 11 months old 
(34 children) while those 28 and 31 months old had the 
lowest frequencies.  
 
Majority of the children, 260 (63.2%), received vaccines 
from the same manufacturer, while 155 (36.6%) and 1 
(0.23%) had two and three doses from two and three 
different manufacturers (GSK, Belgium; Berna Biotech, 
Korea; Panacea Biotech, India) respectively. The major-
ity of children, 333 (78.5%), took the vaccines at sched-
ule times as compared to 91 (21.5%) who did not.  
 
Two hundred and ninety-two (68.9%) of the children 
were reported as having been EBF for the first 6 months 
of life while 132 (31.1%) had supplementary feeding. 
Details of the characteristics of the children have been 
summarized in Table 1. 
 
T6, 10, 14, if the child received the vaccine on the schedule 
time of life at 6, 10, 14 weeks of age; V1/>1, the number 
of vaccines the child took from different manufacturers; 
EBF, exclusive breast feeding during the first six 
months of life. 
 
Table 1 Characteristics of children with completed 
DTP-HBV-Hib vaccination (n=424) 
Characteristics Description 
Mean Age 13.73±5.72 
[5-32months] 
Male 209 (49.3%) 
Female 215 (50.7%) 
T6,10,14 (yes) 333 (78.5%) 
V1/>1 (only one type) 260 (63.2%) 
 
Hepatitis B viral markers 
The prevalence of anti-HBs among the children was 358 
(84.4%), while 3 (0.05%) of the 66 non-responders were 
positive for HBsAg. These 3 were 10, 17 and 23 months 
of age. Of the 358 who had anti-HBs, 340 (95.0%), 205 
(57.3%) and 16 (4.5%) had titres ≥10 mIU/ml, ≥100 
mIU/ml and ≥1000 mIU/ml respectively. Only one 
HBsAg positive child had the mother show evidence of 
HBsAg reactivity during pregnancy in her antenatal 
record book. No record was available to ascertain if the 
child had received prophylaxis at birth. 
 
After initial screening for anti-HBc IgG in 354 children 
who were reactive for anti-HBs, 308 (87.0%) were non-
reactive while 45 (12.7%) were reactive. Supplemental 
testing of 21 reactive samples from the initial anti-HBc 
IgG screening using a second ELISA (Anti Corase, 
General Bioilogicals corp., Taiwan), showed 6 positives 
which all had Optical Density/cut-off ratio of the ELISA 
being >2. It is therefore unlikely that the 24 (53.3%) of 
the 45 initially reactive plasma samples with low 
OD/cut-off ratios (1.01 to 1.44) in the first anti-HBc 
IgG screening were positive. 
 
Determination of correlates for seroconversion and 
sero-protection 
The ages of the children affected the seroconversion rate 
and sero-protective levels for anti-HBs (≥10 mIU/ml) 
(Table 2). EBF, gender, T6, 10, 14, and V1/>1 did not de-
termine if a child would have the minimum protective 
levels of anti-HBs or not (Table 2). When considering a 
minimum titre of 100 mIU/ml. the age of children and 
V1/>1 significantly influenced outcomes (Table 2).  
 
A scatter plot of the actual anti-HBs titres for 230 chil-
dren (r=-0.155; p=.019) who had anti-HBs titres availa-
ble, and 171 (r=-0.190; p=.013) whose anti-HBc IgG 
were confirmed as non-reactive, established that age 










                                                                                                                                                                               
 
 
                                                                                                                                                                               




Reponses after completion of 3 vaccine doses (N=424) 
 Seroconversion Sero-protection (≥10 mIU/ml)       ≥100 mIU/ml 
Variables Anti-HBs No response p value ≥10 mIU/ml <10 mIU/ml p value ≥100 mIU/ml <100 mIU/ml p value 












































































EBF, exclusive breast feeding; Single Vaccine, infants vaccinated with vaccine from only one pharmaceutical company; T6, 10, 14, infants received 




Figure 1 A scatter-plot showing the relationship be-
tween the ages of the children and the actual anti-HBs 
titres. 
 
After regression analysis, age had the tendency to be the 
most important determinant for seroconversion 
(OR.908, CI .908-.992) and sero-protection (OR .953, 
CI .915-.993).  
 
 
Even though this tendency was still relevant when con-
sidering anti-HBs titres ≥ 100 mIU/ml (OR .964, CI 
.931-.999), V1/>1 (OR 1.588, CI 1.052 – 2.397) was the 
most important determinant (Table 3). 
 
Table 3 Significant factors affecting anti-HBs responses 
in vaccinated infants 
 
Relationships between variables 
Children who received vaccinations in a timely manner 
were more likely to have used vaccines from a single 
rather than 2 or more manufacturers (χ2=5.452, p=.020).  
 
Furthermore, the mean age of those who used a single 
type of vaccines was higher (14.75 ± 6.056 months; 
n=268) than those who used vaccines from two or more 
manufacturers (11.96 ± 4.645 months; n=156), <.001 
(CI: -3.897 – 1.688). 
 
DISCUSSION 
Anti-HBs levels Significant 
contributors 
OR CI p value 
Seroconversion Age .949 .908 - .992 .022 
Sero-protection 
(≥10 mIU/ml) 
Age .953 .915 - .993 .021 
≥100 mIU/ml Age .964 .931 - .999 .041 
V1/>1 1.588 1.052 – 2.397 .028 
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Sero-protection rates due to HBV vaccination during the 
EPI have been shown to be high in children within the 
West African sub-region 6,10,11, even though some evi-
dence suggests that this may not be universal 6. Several 
reasons may have been adduced for the low protective 
levels in Senegalese children in a previous study 6, but it 
is also possible that the results may reflect a genetic 
problem 14. Admittedly, different assays and slightly 
modified vaccination schedules may have been used for 
the various studies.  
 
However, the use of different assays in them may not be 
problematic when comparing results from different 
studies. The standardization of the different assays to 
international units may reduce the differences between 
assays and therefore make results comparable. Perhaps 
the use of a different vaccine or genome wide associa-
tion studies, may confirm the actual reasons for the low 
response in Senegalese as compared to Cameroonian, 
and by extension, Ghanaian children 6. 
 
Since the prevalence of anti-HBc in vaccinated infants 
and children is likely to be low 4, it suggests that majori-
ty of the study subjects with low ELISA optical densi-
ty/cut-off ratios were unlikely to have anti-HBc. Thus 
the findings that the age of the children was of signifi-
cant importance for sero-protection is of concern. It 
seems that the older children in this study had taken 
vaccines from particular manufacturers and this may 
reflect on the procurement processes which occurred at 
the time.  
 
This is because the children whose T6, 10, 14 were not on 
schedule were more likely to have used vaccines from 
different manufacturers. Irrespective of the fact that a 
delayed second dose may have some effects on vaccina-
tion outcomes 27, there was no significant lack of protec-
tion for those who did not take the vaccine in a timely 
manner. Unfortunately, this study did not collate the 
kind of data to deeply analyse this assertion. The issue 
related to the procurement of the pentavalent DTP-
HBV-Hib vaccine has also been brought to the fore by 
this study. In resource limited countries where procure-
ment issues may not be stable, different vaccines from 
several companies may be combined during the regular 
schedule of the EPI. In this study however, the results 
suggest that those with the combination of vaccines 
were more likely to have better responses and this may 
be because the younger children were the ones who 
used the mixture of vaccines.  
 
In the face of the possibility of declining titres with age 
irrespective of the vaccination schedule of infants5,17, 
and the loss of immune memory8, 28, it may be important 
to consider 100 mIU/ml as the desired response after 
vaccination since the use of either one or multiple vac-
cines from different manufacturers significantly con-
tributed to that level of protection. 
 
Though maternal HBsAg testing is the most effective 
way to identify infants exposed to HBV who need post 
exposure immunoprophylaxis, the use of a birth dose to 
infants will also serve to prevent perinatal infection 
among infants born to HBsAg-positive pregnant women 
who are not identified or have limited resources to pur-
chase the Hepatitis B immune globulin (HBIG). A birth 
dose for all neonates may therefore be useful to prevent 
loss of immune recognition at a much older age as seen 
elsewhere 29.  
 
However, for those who did not receive the birth dose, 
an early booster dose may be helpful 16. It is noteworthy 
to mention that in developing countries where there are 
also hard to reach populations, majority of infants who 
benefit from the vaccination program may never have 
the opportunity to take boosters. The need to evoke high 
enough anti-HBs during infancy is therefore of para-
mount importance. 
 
In Ghana, the use of vitamin A has been shown not to 
contribute significantly to response to HBV vaccination 
11. However, malnutrition may be responsible for the 
low response to vaccine 6. In this study, there was no 
statistical difference in EBF for those with or without 
sero-protection suggesting that the relationship between 
nutrition or nutrition supplements and immune response 
to HBV vaccination needs further study. 
 
Even though limited data on HBV infections in children 
is available 21,30, the prevalence rates observed in these 
studies were fairly high. The anti-HBs sero-protection in 
this study may be similar to others done in Ghana with 
different primary foci 11,20, however none of these stud-
ies considered the prevalence of HBsAg carriage in vac-
cinated children. Considering the hyper endemic envi-
ronment in which this study was done, and HBsAg 
prevalence in vaccinated children in other West African 
countries 10,31, it may be conclusive to say that the im-
mediate results of the vaccination programme covering 
the study period are desirable. The three children who 
had HBsAg carriage may therefore have had mothers 
who were also carriers.  
The main challenge here is to ensure that protocols de-
veloped for pregnant women who are HBsAg carriers 
are adhered to13, and the universal screening of pregnant 
women for HBsAg should be aggressively pursued and 
vaccination of all infants at birth considered.32 There is 
also the possibility that these children may have been 
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CONCLUSION 
There is still a residual possibility of infection with 
HBV in spite of infant vaccination but it is unclear if 
these infections may have occurred before or after com-
pletion of vaccination. It is therefore important to ac-
quire pre- and post-vaccination outcomes in children so 
as to understand the transmission patterns causing this 
residual infection. National data and urgent protocols 
are therefore needed to ensure that the progress in re-
ducing or elimination of HBV infections in Ghana can 
be effectively monitored. The responses to the HBV 
component of the pentavalent DTP-HBV-Hib vaccine 
are encouraging but the introduction of a birth dose for 
all neonates may be desirable. A booster dose during 
early childhood may also be helpful for young children. 
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